PURPOSE: High pacing threshold (HPT) and very high pacing threshold (VHPT) are known to have a negative impact on leadless pacemaker battery longevity, representing the most common reason for device repositioning. In this study, we evaluated if intraoperative electrical parameters recorded during Micra™ VR implant would be able to predict device performance during follow-up (FU). METHODS: A total of 93 patients undergoing Micra™ VR implant were retrospectively considered. Patients were enrolled in the study if electrical assessment was performed at least twice at implant, at Micra™ final positioning and after removal of the delivery system. All patients received a FU visit at 1 and 12 month after discharge. R-wave sensing amplitude, pacing threshold (PT), and impedance were recorded at each visit. RESULTS: When compared to the first assessment, R-wave sensing amplitude increased by 19.1% after 13 ± 4 min (+ 1.71 ± 0.2 mV, 95% CI 1.4 to 2.02; p < .001). Conversely, there was a significant PT decrease of 22.1% at 12-month FU (- 0.22 ± 0.03 V, 95% CI - 0.13 to - 0.31; p < .001). Among patients with HPT, acute increase of R-wave sensing of 1.5 mV after 14 ± 4 min predicted a significant reduction of PT below 1 V/0.24, at 12-month post-implant (R = 0.72, 95% CI 0.13 to 0.33, p < .001), with a sensitivity of 87.5% (95% CI 0.61-0.98) and a specificity of 88.8% (95% CI 0.51-0.99). CONCLUSION: A 1.5-mV increase in R-wave amplitude at implant is predictive of PT normalization (< 1.0 V/0.24 ms) at 12-month FU. This finding may have practical implications for device repositioning in case of HPT recording at implant.
PURPOSE: High pacing threshold (HPT) and very high pacing threshold (VHPT) are known to have a negative impact on leadless pacemaker battery longevity, representing the most common reason for device repositioning. In this study, we evaluated if intraoperative electrical parameters recorded during Micra™ VR implant would be able to predict device performance during follow-up (FU). METHODS: A total of 93 patients undergoing Micra™ VR implant were retrospectively considered. Patients were enrolled in the study if electrical assessment was performed at least twice at implant, at Micra™ final positioning and after removal of the delivery system. All patients received a FU visit at 1 and 12 month after discharge. R-wave sensing amplitude, pacing threshold (PT), and impedance were recorded at each visit. RESULTS: When compared to the first assessment, R-wave sensing amplitude increased by 19.1% after 13 ± 4 min (+ 1.71 ± 0.2 mV, 95% CI 1.4 to 2.02; p < .001). Conversely, there was a significant PT decrease of 22.1% at 12-month FU (- 0.22 ± 0.03 V, 95% CI - 0.13 to - 0.31; p < .001). Among patients with HPT, acute increase of R-wave sensing of 1.5 mV after 14 ± 4 min predicted a significant reduction of PT below 1 V/0.24, at 12-month post-implant (R = 0.72, 95% CI 0.13 to 0.33, p < .001), with a sensitivity of 87.5% (95% CI 0.61-0.98) and a specificity of 88.8% (95% CI 0.51-0.99). CONCLUSION: A 1.5-mV increase in R-wave amplitude at implant is predictive of PT normalization (< 1.0 V/0.24 ms) at 12-month FU. This finding may have practical implications for device repositioning in case of HPT recording at implant.
Authors: Dwight Reynolds; Gabor Z Duray; Razali Omar; Kyoko Soejima; Petr Neuzil; Shu Zhang; Calambur Narasimhan; Clemens Steinwender; Josep Brugada; Michael Lloyd; Paul R Roberts; Venkata Sagi; John Hummel; Maria Grazia Bongiorni; Reinoud E Knops; Christopher R Ellis; Charles C Gornick; Matthew A Bernabei; Verla Laager; Kurt Stromberg; Eric R Williams; J Harrison Hudnall; Philippe Ritter Journal: N Engl J Med Date: 2015-11-09 Impact factor: 91.245
Authors: Paul R Roberts; Nicolas Clementy; Faisal Al Samadi; Christophe Garweg; Jose Luis Martinez-Sande; Saverio Iacopino; Jens Brock Johansen; Xavier Vinolas Prat; Robert C Kowal; Didier Klug; Lluis Mont; Jan Steffel; Shelby Li; Dirk Van Osch; Mikhael F El-Chami Journal: Heart Rhythm Date: 2017-05-11 Impact factor: 6.343
Authors: Gianfranco Mitacchione; Marco Schiavone; Alessio Gasperetti; Maurizio Viecca; Antonio Curnis; Giovanni B Forleo Journal: Rev Cardiovasc Med Date: 2021-06-30 Impact factor: 2.930
Authors: Philippe Ritter; Gabor Z Duray; Clemens Steinwender; Kyoko Soejima; Razali Omar; Lluís Mont; Lucas V A Boersma; Reinoud E Knops; Larry Chinitz; Shu Zhang; Calambur Narasimhan; John Hummel; Michael Lloyd; Timothy Alexander Simmers; Andrew Voigt; Verla Laager; Kurt Stromberg; Matthew D Bonner; Todd J Sheldon; Dwight Reynolds Journal: Eur Heart J Date: 2015-06-04 Impact factor: 29.983
Authors: Anna Polewczyk; Wojciech Jacheć; Maciej Polewczyk; Dorota Szczęśniak-Stańczyk; Andrzej Kutarski Journal: J Clin Med Date: 2022-07-06 Impact factor: 4.964
Authors: Kevin Willy; Christian Ellermann; Florian Reinke; Benjamin Rath; Julian Wolfes; Lars Eckardt; Florian Doldi; Felix K Wegner; Julia Köbe; Nexhmedin Morina Journal: J Cardiovasc Dev Dis Date: 2022-08-10